Right there with ya'. I think that their thumbs have been on the DVAX scale as well.
DVAX has over 262MM shares outstanding. Call it 265MM shares.
At $5 per share, GSK could buy DVAX in cash for less than $2BB, less than $1.5BB in fact (a little over $1.3BB to be precise).
If you throw in fees, intangibles, all the blah-blah related to the cost of deal-making, you could figure the number as high as $7 per share for all 265MM shares of DVAX. And the cost would rise to $1.8+ BB for GSK.
STILL less than $2BB cost to GSK.
GSK could end all of the arguements, hype, garbage, small-talk and #$%$ over DVAX and have exclusive rights to ALL of it. YET, STILL they don't buy Dynavax. Reverse split becomes the preferable (unnecessary) alternative???
A current check of GSK's key statistics shows that they over $9BB cash on hand and do in excess of $40BB revenue in the last quarterly snapshot. But R/S makes more sense.
Why help and buy out your so-called friends, when you can watch them stumble and crush them and then get the spoils for free? Thanks for nothing, Earle Grey.
2 Specific and recent examples from my own personal experience.
1.) RBS stock.
I was trading in it back in 2008.
I woke up one moring back in late 2008 and went on the computer to check morning news, etc before market open.
My RBS was WAY up and I was overjoyed for a few minutes until I found the reason why.
RBS had enacted a 20 for 1 reverse split without a vote or any prior notice of it coming.
Shocked and dismayed, I consulted the advice of a guy who worked for Morgan Stanley at the time and asked if I would ever get back to the zero point where I was befor the split. The man's advisement was, "most likely not" and that I should consider some type of exit strategy for my holdings in the stock.
I waited for an upswing and took my best exit opportunity which presented itself.
Painful, but I survived it largely intact.
Look at a basic chart on Yahoo for RBS. Make the length setting for "max". You'll see the event which I am talking about.
You'll also see that RBS is far, FAR below that R/S point today.
2.) VSGN. Vasogen. A #$%$ Canadian biotech stock from back aroung 2006-2008.
In either 2006, 2007 they set up a (I believe) 5 for 1 reverse split which was done by a vote at an AGM; like what is proposed here.
Long story short, the R/S happened, the stock went from less than $1 to $3.50 and within 1 year of the R/S was back under a dollar.
By 2010 the stock had been REVERSE MERGERED into a company called intellipharmiceutics IPCI.
IPCI only wanted the cash and the shareholders got nothing.
3.) My Father was in RAD before he passed away and they announced a R/S but would not say the size of it..
I told him that he shouldn't wait around for it, get out with what he could. Today RAD has managed to fight it's way back to $5 or $6, but they had some pretty rough years in between.
And DVAX has no stores of anything to sell, unlike RAD. At least they had SOMETHING to sell to keep going.
I don't subcribe to Biryeeni or whoever you mentioned. But I remember.
"If you know what's.... .....play it.*"
For instance, if you know an earth quake or tsunami are imminent, be somewhere else when it arrives. Somewhere far away. For me, the same applies to reverse splits.
Anyone still confused about Earl Grey being the big savior? He just set us up for the next boning.
That was their big plan of how to get to $4.50 per share? It's not true share price growth, and the stupid market will act like the company just did some big work and boosted their share price, which they most definitely didn't. They had a fat-ectomy and cut off a whole bunch of their shareholders; and that is supposed their big effort??? Bogus.
Guess who shows up right after an R/S goes into effect? The shorts. The share price just jumped, so they show up to start cutting more off.
Reverse splits are the worst; that is how they physically steal from you.
I've seen this before and it doesn't end well. It will most likely be 10 for 1, because that is what they gave themselves room for. Just bogus.
Looks like GSK just won another battle and fabulous Earl Grey handed it to them on some velvet pillow.
Yup, I think you are right. We are alway the last to find out the hammer is on it's way.
I'll say it again, Earl Grey isn't helping Dynavax. He is helping GSK to Dynavax.
Which "big pharma" were you referring to? GSK? Big freaking surprise! Been there, done that.
It's thinking like what you display that if it were never countered, things like polio would never have been cured.
Big money can only stand in the way of things for so long, eventually "progress" wins out.
If you don't like the company and stock that's fine, you know what to do (just go away)........
The EXACT answer to that would be, "someone who has nothing more to lose".
One other idiot told me that I should be on drugs for owning DVAX; I didn't listen to him either.
If this stock isn't for you and you have no more bad advice to dispense, then you should just move along to somewhere else better.....
And how, exactly, would that be any different from last summer (which was abysmal)???
Yeah, I think it's important to "get it right" with medicines (even if it takes 10 attempts to do so).
Airplanes and submarines are other places where things need to be "gotten right (the first time)".
I certainly don't want to take any of the medicine which "got it wrong". ;-)
Yes, apparently a tree has fallen over somewhere in the forest. Let's hope that someone important on wall street heard it and that it made a pleasant noise to them. ;-)
Into the breach we go once more, my friend, pray no SAE's and that it meets primary endpoints.
I think that Heplisav is one of the most over-tested compounds, without approval that I've ever seen.
I really do hope that in the end we finally get success from this; at least it will only take a year to get through.
Hope for the best,.....
(Investor's Business Daily) that GSK has paid $40MM to buy some health care unit of an Indonesian company called, Saravati Venture Capital. GSK shares dropped 2 cents due to the buy out.
??? $40MM and all it dents GSK is 2 lousy centavos!!!!????
C'mon already GSK! Spend a little more and you can have dVAX! They won't feel any big effect from that either...........
Where you beeeeeeeeeeeeeeeeen, duuuuuuuuuuuuuuuuuuuude??????
LOOOOOOOOOOOOOOOOOOOONG time noooooooooooooo heeeeeeeeeeear.
What upppppppppppppppppppp man? ;-) :-) :-) :-) :-)
I don't know (about the MIA item).
Well, that is interesting, anyways.
Thanks for the list OJ. That seems to be current to say the least.
At least we know where AZ1419 is, for sure; they just updated that one last week.
The rest, I suppose we just have to wait for. Same as always.
It would be nice to know but, management is NEVER going to tell us what they are saying privately to these larger banks, etc. It's the nature of their game.
The current trial number for the SD-101 compound is NCT01745354.
I also found one which is active but no yet running for Heplisav (November of 2013), The trial number for it is: NCT01999699. It's a study of Heplisav in healthy older adults (50-70).
Check out the official title for it; what the hell is going on with this company? Why are they now doing P1 trials again on Heplisav????
Official Title: A Phase 1 Systems Biology Study to Investigate Immune Correlates of the Response to an Experimental Hepatitis B Vaccine (HEPLISAV) in Healthy Adults 50 to 70 Years of Age.
DV1179 was in P1 back in 2011. Last printed article which I could find about it was in April of 2011 and it indicated that they were expecting data from it in late 2011.
Puff and smoke, and that's it.
Where did it go.
It doesn't appear on the trials website, anywhere. Not under Dynavax, not under GSK, not under "DV1179".
It never went to P2, there don't seem to be any published results of anything from P1, and it's GSK's baby.
One way trip to the Bermuda Triangle of trials and compounds? I think, more likely, that it got caught in negotiations with Heplisav along with GSK. No movement on either one of them.
No further development, no milestones. 2 years later and it hasn't gone to P2??? Very odd.
There are indications of SD-101 being in enrollment, but no one seems to be partnered to that one.
That one is for Lymphoma (and Hep C). The FDA LOVES cancer compounds. That could be the one to go with; but will GSK allow it?
Interesting. Is this trial still running? Where is it at, in terms of completion?
Supposedly, Dynavax qual'ed for a $6MM milestone for the project initiation. That money must have already been received and burned already #$%$ and new grape vines for cimmarosa, probably).
Hopefully, we see a little movement out of this program (a little is better than nothing).